hit counter
Biogen Inc. (BIIB) Stock News Sentiment & Price - Sentifly
BIIB - Sentifly


Profile

Watchlist

Your watchlist is empty. Go add some tickers to it!



Biogen Inc. (BIIB)

USA
Biotechnology
NASDAQ
BIIB Price and Sentiment
1MO
1D
Positive, Negative
Loading chart...
BIIB Latest news
GlobeNewsWire
Neutral
New Phase 3 Data Show Positive Correlation Between ADUHELM™ Treatment Effect on Biomarkers and Reduction in Clinical Decline in Alzheimer's Disease
2021-11-11 17:10

CAMBRIDGE, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Eisai Co., Ltd. (Tokyo, Japan) announced that data from approximately 7,000 plasma samples from more than 1,800 patients in the ADUHELM™ (aducanumab-avwa) Phase 3 clinical trials showed a statistically significant correlation between plasma p-tau reduction and less cognitive and functional decline in Alzheimer's disease. Reductions in plasma p-tau181 were also correlated with a lowering of amyloid beta plaque. The pre-specified analysis of plasma samples was conducted by an independent lab, drawing from the two pivotal ADUHELM Phase 3 EMERGE and ENGAGE trials. The findings were presented today at the Clinical Trials on Alzheimer's Disease conference (CTAD), held November 9-12 virtually and in Boston, Massachusetts.

Benzinga
Positive
Eisai Posts New Lecanemab Data From Mid-Stage Alzheimer's Trial
2021-11-11 12:58

Eisai Co Ltd (OTC: ESALY) and Biogen Inc (NASDAQ: BIIB) announced results of sensitivity analyses evaluating the consistency of lecanemab efficacy results across multiple statistical models in patients with Mild Cognitive Impairment (MCI) due to Alzheimer's disease (AD) and mild AD. The data were presented at the 2021 Clinical Trials on Alzheimer's Disease (CTAD) conference.

PRNewsWire
Neutral
Eisai Presents New Analysis Of Lecanemab Clinical Efficacy Results From Phase 2b Study At Clinical Trials On Alzheimer's Disease (CTAD) Conference
2021-11-11 11:20

TOKYO and CAMBRIDGE, Mass., Nov. 11, 2021 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Michel Vounatsos, "Biogen") announced today results of sensitivity analyses evaluating the consistency of lecanemab efficacy results across multiple statistical models in patients with Mild Cognitive Impairment (MCI) due to Alzheimer's disease (AD) and mild AD (collectively known as early AD). This presentation was made by Eisai at the 2021 Clinical Trials on Alzheimer's Disease (CTAD) conference, November 9-12, 2021 in Boston, Massachusetts and virtually.

Seeking Alpha
Neutral
Biogen Vs. Cassava Sciences Stock: Which Is The Better Buy?
2021-11-11 10:30

Neurological diseases including Alzheimer's are a huge unmet need that BIIB and SAVA are working on solutions for. BIIB's diversification, low sentiment, and profitability make it more suitable to a wider audience of investors.

Benzinga
Negative
Hit By Slow Rollout, Biogen's Aduhelm Could Soon Find Itself In Price Competition: Reuters
2021-11-10 12:37

With already a snail-paced rollout of Biogen Inc's (NASDAQ: BIIB) controversial Alzheimer's treatment Aduhelm, the Company could soon face price competition. Companies like Roche Holdings AG (OTC: RHHBY) and Eli Lilly And Co (NYSE: LLY) are already lining up reviews for their own Alzheimer's candidates.

Seeking Alpha
Positive
An Alzheimer's Bubble That Was Well & Truly Burst May Be Blowing Up Again - Here's Why
2021-11-10 11:15

An Alzheimer's Bubble That Was Well & Truly Burst May Be Blowing Up Again - Here's Why

Zacks Investment Research
Neutral
How Are Biotech ETFs Reacting to These Q3 Earnings Releases?
2021-11-06 00:50

Let's take a look at some big biotechnological earnings releases to see if these will impact ETFs exposed to the space.

GuruFocus
Neutral
The Vanguard Health Care Fund's Top 5 Trades of the 3rd Quarter
2021-11-03 16:14

The Vanguard Health Care Fund (Trades, Portfolio) recently released its portfolio updates for the third quarter of 2021, which ended on Sept. 30.

GlobeNewsWire
Neutral
Biogen Announces Late Breakers and Additional New Data Presentations at the 2021 Clinical Trials on Alzheimer's Disease (CTAD) Meeting
2021-11-03 07:30

CAMBRIDGE, Mass., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced the company will present a variety of new data from its Alzheimer's disease product portfolio and clinical development pipeline at the upcoming annual Clinical Trials on Alzheimer's Disease conference (CTAD), held November 9-12 virtually and in Boston, Massachusetts. Biogen's contributions to the conference are driven in part by analyses from the largest clinical trial dataset in early Alzheimer's disease research. This includes over 3,000 patients in Phase 3 trials and approximately 1,700 patients in the ADUHELM (aducanumab-avwa) redosing trial, EMBARK.

Seeking Alpha
Neutral
Biogen's Long Aduhelm Game
2021-11-02 11:53

Aduhelm (aducanumab) sales got off to a very slow start in Q3.

Loading more news...